Skip to main content
S&P 5007,722.72+0.73%DOW51,176.96+0.49%NASDAQ27,190.86+1.19%BTC$84,654.00-0.13%ETH$2,677.39-1.09%GOLD$4,172.10-0.72%OIL$91.26-1.73%
Smart Investors Daily
SID Premium
PG

NASDAQ · PGEN

Precigen, Inc.

Healthcare · Biotechnology

$8.54

Up+$0.33 (+4.02%)

Updated Oct 5, 2026, 8:18 AM

SID Score

6.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.09B
P/E ratio
-2.51
Dividend yield
0.00%
52-week range
$2.99 – $8.98
Volume
6.36M
Avg. volume
4.88M

Price performance · PGEN

PGEN price history

1M range · 19 trading sessions · Daily adjusted prices

Prices through Oct 2, 2026

PGEN closed at $8.54 after 19 trading sessions, up 24.31% for the selected period.

Last close
$8.54
Period change
+24.31%
Period low
$6.68
Period high
$8.56
Daily close
View OHLC price history
PGEN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 2, 2026$8.30$8.55$8.18$8.546.36M
Oct 1, 2026$8.50$8.64$8.19$8.214.61M
Sep 30, 2026$8.13$8.98$8.09$8.5611.69M
Sep 29, 2026$7.80$8.10$7.80$8.054.14M
Sep 28, 2026$7.61$7.86$7.50$7.813.49M
Sep 25, 2026$8.08$8.27$7.63$7.756.56M
Sep 24, 2026$7.37$7.755$7.325$7.704.62M
Sep 23, 2026$7.95$8.01$7.19$7.445.56M
Sep 22, 2026$7.64$8.04$7.52$7.895.33M
Sep 21, 2026$7.84$7.91$7.63$7.703.24M
Sep 18, 2026$7.98$8.0385$7.695$7.789.58M
Sep 17, 2026$7.585$7.945$7.585$7.879.36M
Sep 16, 2026$7.00$7.49$6.94$7.4358.23M
Sep 15, 2026$6.81$7.015$6.76$7.002.78M
Sep 14, 2026$6.86$7.11$6.83$6.852.83M
Sep 11, 2026$6.77$6.92$6.76$6.852.06M
Sep 10, 2026$6.70$6.73$6.54$6.682.84M
Sep 9, 2026$6.87$6.885$6.675$6.803.14M
Sep 8, 2026$6.89$7.02$6.72$6.872.77M

Latest PGEN news

The latest Smart Investors Daily articles mentioning PGEN.

Stock researchCompany · Overview

PGEN research

Overview

Company profile and research snapshot.

Company profile

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.00
Implied upside
—
Analysts
—
PGEN recent ratings
DateFirmRatingTarget
Sep 25, 2026B. Riley SecuritiesBuy—
Aug 5, 2026HC Wainwright & Co.Buy—
Aug 3, 2026HC Wainwright & Co.Buy—
May 28, 2026HC Wainwright & Co.Buy—
May 14, 2026CitizensMarket Outperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?

Precigen, Inc. (NASDAQ:PGEN) announced on September 21 that the FDA granted Platform Technology Designation to AdenoVerse, the technology behind the approved medicine PAPZIMEOS. The designation creates opportunities to reuse manufacturing and preclinical knowledge in future drug applications, potentially reducing work that would otherwise need to be repeated. For Precigen, Inc. (NASDAQ:PGEN), the investment question is […]

Yahoo · Sep 26, 2026

Precigen (PGEN) Gains FDA Platform Backing, Is The Stock Still Cheap?

Precigen (PGEN) is back in focus after the United States Food and Drug Administration granted platform technology designation to its AdenoVerse immunotherapeutic platform, which underpins the recently approved PAPZIMEOS therapy. The recent FDA platform technology designation and the earlier approval of PAPZIMEOS have coincided with a sharp shift in market sentiment toward Precigen, with the share price delivering an 81.07% year-to-date return and a very large 3-year total shareholder return...

Yahoo · Sep 25, 2026

Precigen (PGEN) Secures FDA Platform Status For AdenoVerse And Future Therapies

Precigen (NasdaqGS:PGEN) said the FDA has granted platform technology designation to its AdenoVerse immunotherapeutic platform. The designation applies to the AdenoVerse platform rather than a single drug, covering multiple potential future product candidates across indications. FDA platform technology status can allow certain data and review learnings from one product to support later candidates built on the same backbone. The new FDA platform technology designation for AdenoVerse sits...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By